By Naveen Pemmaraju, MD
John Mascarenhas, MD
Ruben A. Mesa, MD
Jeanne M. Palmer, MD
Stephen Oh, MD, PhD
John Mascarenhas, MD
Ruben A. Mesa, MD
Jeanne M. Palmer, MD
Stephen Oh, MD, PhD
Key opinion leaders on myeloproliferative neoplasms review the potential of CALR as a therapeutic target following data from the ASH 2022 Annual Meeting.